Sort   by:  
 Page size 
TranscriptomicsGene expression profiling of MDA231, BT549, and SUM159PT cells after selumetinib treatment or DUSP4 siRNA knockdown
MDA231, BT549, and SUM159PT basal-like breast cancer cell lines were transfected with non-targeting siRNA (siCONTROL), siRNA targeting DUSP4 (siDUSP4), or siCONTROL + 4 or 24 hr of 1uM selumetinib. Cells were harvested at 96 hr post-siRNA transfection. Data were Log2 RMA normalized. We sought to i...
ORGANISM(S): Homo sapiens 
2013-09-03 | E-GEOD-41816 | biostudies-arrayexpress
TranscriptomicsInvestigation of gene expression signature induced by Alk5TD (active type I TGF-beta receptor)
BT474 cells stably expressing Alk5TD or vector (BT474-Alk5TD and BT474-pBMN, respectively) were compared for gene expression. Genes that were differentially expressed between the two cell lines were collected as the signature induced by Alk5TD expression. Keywords: Comparison of two cell types (BT47...
ORGANISM(S): Homo sapiens 
2008-04-29 | E-GEOD-11293 | biostudies-arrayexpress
TranscriptomicsBreast cancer cells resistant to hormone deprivation maintain an estrogen receptor alpha-dependent, E2F-directed transcriptional program
A significant fraction of breast cancers exhibit de novo or acquired resistance to estrogen deprivation. To model resistance to aromatase inhibitor (AI) therapy, long-term estrogen-deprived (LTED) derivatives of MCF-7 and HCC-1428 cells were generated through culture for 3 and 7 months under hormone...
ORGANISM(S): Homo sapiens 
2012-05-13 | E-GEOD-22533 | biostudies-arrayexpress
TranscriptomicsTranscription profiling of estrogen receptor positive breast cancer cell lines after long term estrogen deprivation
Hyperactivation of phosphatidylinositol-3 kinase (PI3K) promotes escape from hormone dependence in estrogen receptor-positive breast cancer. A significant fraction of breast cancers exhibit de novo or acquired resistance to estrogen deprivation. We used gene expression microarrays to identify genes...
ORGANISM(S): Homo sapiens 
2010-06-23 | E-GEOD-19639 | biostudies-arrayexpress
UnknownStand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.
Not available
S-EPMC3986383 | biostudies-literature
UnknownPhase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003).
Not available
S-EPMC4534525 | biostudies-literature
TranscriptomicsConditional loss of ErbB3 delays mammary gland hyperplasias induced by mutant PIK3CA but does not affect mammary tumor latency, gene expression or signaling
Mutations in PIK3CA, the gene encoding the p110α subunit of PI3K, induce transformation of mammary epithelial cells (MEC). Studies suggest the transforming action of mutant PIK3CA requires binding to activated receptor tyrosine kinases or adaptors. We examined in transgenic mice if ErbB3, a powerful...
ORGANISM(S): Mus musculus 
2013-06-20 | E-GEOD-43037 | biostudies-arrayexpress
TranscriptomicsControlled ErbB receptor dimerization
In order to better understand signaling events following receptor dimerization involving HER2, we have generated an experimental system in which ErbB dimerization can be controlled. We used gene expression microarrays to identify genes and pathways that are differentially activated by HER2 homodimer...
ORGANISM(S): Homo sapiens 
2011-05-13 | E-GEOD-22288 | biostudies-arrayexpress
TranscriptomicsMutant PI3K cooperates with HER2 to promote mammary tumor formation and induces trastuzumab resistance in vivo
HER2 (ERBB2) gene amplification and PIK3CA mutations often co-occur in breast cancer, and aberrant activation of the PI3K pathway has been implicated in resistance to HER2-directed therapies. We have created a mouse model of HER2-overexpressing (HER2+), PIK3CAH1047R-mutant breast cancer. Mice expres...
ORGANISM(S): Mus musculus 
2013-09-03 | E-GEOD-41118 | biostudies-arrayexpress
UnknownNeratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial.
Not available
S-EPMC11335023 | biostudies-literature
Sort   by:  
 Page size